GLPG Galapagos NV

Galapagos to Present at Upcoming Investor Conferences

Galapagos to Present at Upcoming Investor Conferences

Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:



TD Cowen 45th Annual Healthcare Conference 

Date: Tuesday, March 4, 2025

Location: Boston, MA

Corporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CET

Live Webcast Link:



Barclays 27th Annual Global Healthcare Conference

Date: Wednesday, March 12, 2025

Location: Miami, FL

Corporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CET

Live Webcast Link:



A live webcast of the presentations can also be accessed on the Investors page of the Company’s website at . Replays of the webcasts will be available following the completion of the event and will be archived for up to 90 days.



About Galapagos

We are a biotechnology company with operations in Europe and the U.S. dedicated to transforming patient outcomes through life-changing science and innovation for more years of life and quality of life. Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class medicines. With capabilities from lab to patient, including a decentralized cell therapy manufacturing platform, we are committed to challenging the status quo and delivering results for our patients, employees, and shareholders. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most. For additional information, please visit or follow us on or .



For further information, please contact:

Media inquiries:

Srikant Ramaswami







Marieke Vermeersch







Investor inquiries:

Srikant Ramaswami







Sandra Cauwenberghs 



3







Forward-looking statements

This press release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Attachment



EN
24/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

 PRESS RELEASE

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Galapagos to Present New Data from Cell Therapy Program at ASH 2025 Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new Phase 2 data highlight the potential of CAR-T cell therapy candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma Results demonstrate high rates of complete and durable responses along with low rates of high-grade toxicities using GLPG5101 manufactured on innovative median seven-day vein-to-vein time platform, potentially enabling broader access to cell the...

 PRESS RELEASE

Galapagos zal nieuwe gegevens presenteren over celtherapieprogramma ti...

Galapagos zal nieuwe gegevens presenteren over celtherapieprogramma tijdens ASH 2025 Mondelinge presentatie van GLPG5101-gegevens uit de ATALANTA-1 studie bij patiënten met hoog-risico recidief/refractair mantelcellymfoom Twee abstracts met nieuwe fase 2-gegevens benadrukken het potentieel van CAR-T-celtherapie kandidaat GLPG5101 in recidief/refractaire non-hodgkin lymfoom Resultaten tonen hoge percentages van volledige en duurzame responsen, gecombineerd met lage percentages van ernstige toxiciteiten met GLPG5101, geproduceerd via een innovatief platform met een mediane vein-to-vein tijd...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SY...

: FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SYENS BB, ECMPA NA

 PRESS RELEASE

Galapagos Announces Changes to its Board to Accelerate Strategic Focus...

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on transformational busine...

 PRESS RELEASE

Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strateg...

Galapagos kondigt wijzigingen aan in de Raad van Bestuur om de strategische focus op business development te versnellen Nieuwe bestuurders brengen sterke financiële leiderschapservaring, expertise in kapitaalallocatie en business development naar de Raad van Bestuur Mechelen, België; 30 oktober 2025, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag verschillende wijzigingen aan in haar Raad van Bestuur, als onderdeel van haar voortdurende inzet voor goed bestuur op de lange termijn en strategische continuïteit. Deze wijzigingen versterken de afstemming van de samenstellin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch